Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data: Difference between revisions
Jump to navigation
Jump to search
(→What) |
|||
| Line 11: | Line 11: | ||
===News=== | ===News=== | ||
===Commons-Based, Peer-Production, and Open Access News=== | ===Commons-Based, Peer-Production, and Open Access News=== | ||
* Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed | |||
==Genentech== | ==Genentech== | ||
Revision as of 21:35, 6 April 2009
NIH
Celera
Amgen
Who
What
- ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
Where
News
Commons-Based, Peer-Production, and Open Access News
- Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
Genentech
Genzyme
Gilead Sciences
Biogen Idec
Cephalon
MedImmune
Celgene
Abraxis BioScience
ImClone Systems
IP Profile of Biggest for-profit companies in BGP